Permission for use of the analytical results and data supporting those results was obtained from Louis Brooks Jr., Vice President, Data Technology and Marketing Analytics at OptumInsight. Search protocols were defined and analysis conducted by Optum Insight personnel at the direction of the authors. The database was not directly accessed by the authors. The data consist of proprietary de-identified administrative health claims data from OptumInsight, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: The authors confirm that, for approved reasons, some access restrictions apply to the data underlying the findings. Received: SeptemAccepted: NovemPublished: December 3, 2014Ĭopyright: © 2014 Brayton et al. PLoS ONE 9(12):Įditor: Gagan Deep, University of Colorado Denver, United States of America The average baseline health care costs were high ($53,422) but decreased in the year after PCD acquisition (−$11,833, p<0.0001).Ĭitation: Brayton KM, Hirsch AT, O′Brien PJ, Cheville A, Karaca-Mandic P, Rockson SG (2014) Lymphedema Prevalence and Treatment Benefits in Cancer: Impact of a Therapeutic Intervention on Health Outcomes and Costs. PCD use was associated with decreases in rates of hospitalizations (45% to 32%, p<0.0001), outpatient hospital visits (95% to 90%, p<0.0001), cellulitis diagnoses (28% to 22%, p = 0.003), and physical therapy use (50% to 41%, p<0.0001). Lymphedema prevalence among cancer survivors increased from 0.95% in 2007 to 1.24% in 2013. The impact of PCD use was evaluated by comparing rates of a pre-specified set of health outcomes and costs for the 12 months before and after, respectively, PCD receipt.
Lymphedema prevalence was calculated: number of patients with a lymphedema claim in a calendar year divided by total number of enrollees.
Analyses were performed for individuals with cancer-related lymphedema (n = 1,065). Patients were required to have 12 months of continuous insurance coverage prior to PCD receipt (baseline), as well as a 12-month follow-up period. Retrospective analysis of de-identified health claims data from a large national insurer for calendar years 2007 through 2013.
0 kommentar(er)
